Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2002AIDS

The utility of inhibitory quotients in determining the relative potency of protease inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

PPPeter J. PilieroBrigham and Women's Hospital

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Peter J. Piliero (2002) studied this question.

synapsesocial.com/papers/6a717bb5ac440176ef2a2b01https://doi.org/10.1097/00002030-200203290-00020
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study2000 · 222 citations
  2. 2In Vitro Effect of α1‐Acid Glycoprotein on the Anti‐Human Immunodeficiency Virus (HIV) Activity of the Protease Inhibitor CGP 61755: A Comparative Study with Other Relevant HIV Protease Inhibitors1997 · 48 citations
  3. 3Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy2000 · 138 citations
  4. 4Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease Inhibitors2000 · 107 citations
  5. 5The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients1996 · 299 citations